Loading stock data…
Loading stock data…
US$2.24
Get one email when LXRX crosses your level. Checked every 15 minutes during market hours.
▲ +0.04 (1.82%)up today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
53.4
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
0.04
Bearish momentumMACD below its signal line (0.06).
50-day average
2.13
Price aboveShort-term trend reference.
200-day average
1.62
Price aboveLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases, particularly in cardiometabolic and neurological areas. It offers Sotagliflozin, marketed as Inpefa and Zynquista, an oral dual SGLT1/2 inhibitor that reduces the risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kid…
www.lexpharma.com3 strong buy · 5 buy · 3 hold · 0 sell · 0 strong sell (11 analysts, 2026-07-01)
3 strong buy · 5 buy · 3 hold · 0 sell · 0 strong sell (11 analysts, 2026-06-01)
3 strong buy · 5 buy · 3 hold · 0 sell · 0 strong sell (11 analysts, 2026-05-01)
3 strong buy · 5 buy · 3 hold · 0 sell · 0 strong sell (11 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-05-29 | 0.74 | 0.92 | ✓ Beat |
| 2026-03-24 | -0.4 | -1 | ✗ Miss |
| 2026-03-13 | 0.05 | 0.07 | ✓ Beat |
| 2026-03-05 | -0.07 | -0.04 | ✓ Beat |
| 2026-01-17 | 0.38 | 0.34 | ✗ Miss |
| 2025-11-06 | -0.07 | -0.04 | ✓ Beat |
| 2025-08-06 | -0.08 | 0.01 | ✓ Beat |
| 2025-05-13 | -0.1 | -0.07 | ✓ Beat |
Companies in the same industry, via Finnhub